Singapore outlines process to register biosimilars posted 19/10/2009
Drugmakers seeking to register a biosimilar product in Singapore should provide complete information on the development, control and manufacture of the drug and its active ingredient, a new guidance says. Comparability studies between the biosimilar product and its reference product also must be submitted, the Health Sciences Authority says in the guidance posted on its website on 1 August 2009.
The guidance document describes the basic principles of a similar biological product, as well as the procedures and requirements for registration of a similar biological product.
The document is intended to:
The guidance document is adapted mainly from the EMEA guidelines on similar biological products, with consideration of Singapore’s local regulatory environment.
References:
Guidance on registration of similar biological products in Singapore, August 2009.
FDAnews Drug Daily Bulletin Vol. 6 No. 188, 28 September 2009. Singapore outlines process to register biosimilars.
Source: FDAnews Drug Daily Bulletin
